Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFRVolker Heinemann, Andreas Jung, Sebastian Stintzing et al.|Cancer Treatment Reviews|2008Cited by 205
Multicentre phase II trial of trastuzumab and capecitabine in patients with HER2 overexpressing metastatic pancreatic cancerJan Harder, Michael Geißler, Gabriele Ihorst et al.|British Journal of Cancer|2012Cited by 184
Left-sided primary tumors are associated with favorable prognosis in patients with KRAS codon 12/13 wild-type metastatic colorectal cancer treated with cetuximab plus chemotherapy: an analysis of the AIO KRK-0104 trialJobst C. von Einem, Dominik Paul Modest, Holger G. Hass et al.|Journal of Cancer Research and Clinical Oncology|2014Cited by 112
pERK, pAKT and p53 as tissue biomarkers in erlotinib-treated patients with advanced pancreatic cancer: a translational subgroup analysis from AIO-PK0104Steffen Ormanns, Stefan Boeck|BMC Cancer|2014Cited by 29